Im SA, Mukai H, Park IH, et al. - In order to evaluate the benefit of palbociclib plus letrozole in Asian women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, researchers analyzed the outcomes of 95 Asian postmenopausal women of 666 enrolled participants in the double-blind, international, phase 3 PALOMA-II study. In PALOMA-2 study, women were randomly assigned 2:1 to receive palbociclib plus letrozole or placebo plus letrozole. Consistent with the overall study population, Asians showed significantly improved progression-free survival with receipt of palbociclib in addition to letrozole. Compared with non-Asians, Asians experienced hematologic toxicities more frequently which were manageable with early dose modifications while maintaining quality of life.